Maxilin

Clarithromycin, the active ingredient in Maxilin, is a macrolide antibiotic presented as an intravenous solution for intravenous use. It treats community‑acquired pneumonia, skin and soft tissue infections, and upper respiratory tract infections in adult patients, especially when rapid high plasma concentrations are required or oral therapy is unsuitable.

GNH USA supplies Maxilin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, including acute and specialty care settings, ensuring reliable product quality and regulatory compliance.

Clarithromycin is a macrolide antibiotic that targets bacterial infections of the respiratory and skin pathways, offering a broad spectrum of activity against susceptible organisms. - Community‑acquired pneumonia: achieves bacterial eradication in the lungs, improving symptoms and reducing mortality in adult patients. - Skin and soft tissue infections: reduces bacterial load in cellulitis, abscesses and wound infections, facilitating faster healing. - Upper respiratory tract infections: eliminates common respiratory pathogens, alleviating cough, sore throat and sinus involvement. - Bronchitis: controls bacterial exacerbations, shortening disease duration and preventing complications.

Clarithromycin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: loose stools, often self‑limiting. - Taste disturbance: altered or metallic taste. - Rash: mild skin erythema.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or jaundice. - QT prolongation: cardiac rhythm disturbance. - Severe allergic reaction: anaphylaxis or angioedema. - Clostridioides difficile colitis: severe diarrhea due to bacterial overgrowth.

Clarithromycin requires careful monitoring in several clinical situations. - Renal impairment: dose adjustment may be required in patients with reduced kidney function. - Hepatic dysfunction: monitor liver enzymes during therapy. - Cardiac risk: avoid in patients with known QT prolongation or electrolyte disturbances. - Drug interactions: review concomitant medications for potential CYP3A4 interactions. - Pregnancy: category B, use only if benefit outweighs risk. - Store at ambient temperature: keep in original container, protect from light and moisture.

Clarithromycin can interact with several medicines; clinicians should assess risk before co‑administration.

Major Interactions (Avoid): - Strong CYP3A4 inducers (rifampin, carbamazepine): may markedly lower clarithromycin exposure. - Anticoagulants (warfarin): increased anticoagulant effect, monitor INR closely. - QT‑prolonging agents (amiodarone, quinidine): risk of serious cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Statins (simvastatin, lovastatin): elevated risk of myopathy, consider dose adjustment. - Theophylline: increased serum concentrations, monitor for toxicity. - Oral contraceptives: possible reduced effectiveness, advise additional contraception.